Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Acq. announced
CC transcript
Employment agrmnt
Coll. bargaining agrmnt
Director departure
|
|
NOVELION THERAPEUTICS INC. (NVLNF)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/07/2019 |
8-K
| Quarterly results|
Docs:
|
"Novelion Therapeutics Reports First Quarter 2019 Financial Results – Company reiterates 2019 guidance of total net revenues between $160.0 and $175.0 million, including approximately $30.0 million of licensing revenues VANCOUVER, British Columbia, and CAMBRIDGE, MA, May 7, 2019 - Novelion Therapeutics Inc. , a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases , today reported financial results for the first quarter ended March 31, 2019. Novelion’s Interim Chief Executive Officer Ben Harshbarger commented, “We continue to execute on our goals of achieving target revenues, maximizing the impact of the operating cost reductions that we implemented in late 2018, working with the FDA on the development program for the poten..." |
|
| 03/14/2019 |
8-K
| Quarterly results|
Docs:
|
"Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results – Company achieves FY 2018 total net revenues of $130.4 million – FY 2018 operating expenses reduced by $27.2 million, or 18.4% VANCOUVER, British Columbia, and Cambridge, MA, March 14, 2019 - Novelion Therapeutics Inc. , a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases , today reported financial results for the fourth quarter and year ended December 31, 2018. Novelion’s Interim Chief Executive Officer Ben Harshbarger commented, “We are pleased with our fourth quarter results which reflect strong revenue performance and show meaningful impact from the cost reduction initiatives executed throughout 2018. We remain focused on undertaking..." |
|
| 11/09/2018 |
8-K
| Quarterly results |
| 08/07/2018 |
8-K
| Quarterly results|
Docs:
|
"Novelion Therapeutics Reports Second Quarter 2018 Financial Results Following recent marketing approval in both generalized and partial lipodystrophy indications, European launch of MYALEPTA® has commenced VANCOUVER, British Columbia, August 7, 2018 - Novelion Therapeutics Inc. , a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases , today reported financial results for the second quarter and six months ended June 30, 2018 and provided an overview of business activities. Interim Chief Executive Officer Jeff Hackman commented, “Under our new leadership team, we are laser focused on maximizing the potential of our two commercial assets, enhancing our operational efficiencies by reducing costs, and fixing our capital struc..." |
|
| 05/10/2018 |
8-K
| Quarterly results|
Docs:
|
"Novelion Therapeutics Reports First Quarter 2018 Financial Results VANCOUVER, British Columbia, May 10, 2018 - Novelion Therapeutics Inc. , a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases , today reported financial results for the first quarter ended March 31, 2018 and provided an overview of business activities. Chief Operating Officer Jeff Hackman said, “Thus far in 2018 we have executed a number of important initiatives, including finalizing the settlements with the DOJ, reducing costs, strengthening our balance sheet with a $20 million term loan, and reviewing our holding and capital structure with a goal of optimizing our assets for shareholders. We have a strong rare disease product portfolio that carries the..." |
|
| 11/09/2017 |
8-K
| Quarterly results |
| 08/08/2017 |
8-K
| Quarterly results |
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 05/02/2013 |
8-K
| Form 8-K - Current report |
| 02/21/2013 |
8-K
| Quarterly results |
| 11/07/2012 |
8-K
| Form 8-K - Current report |
| 08/02/2012 |
8-K
| Form 8-K - Current report |
| 05/03/2012 |
8-K
| Form 8-K - Current report |
| 02/23/2012 |
8-K
| Form 8-K - Current report |
| 11/03/2011 |
8-K
| Form 8-K - Current report |
| 07/28/2011 |
8-K
| Form 8-K - Current report |
| 05/05/2011 |
8-K
| Form 8-K - Current report |
| 03/01/2011 |
8-K
| Form 8-K - Current report |
| 11/03/2010 |
8-K
| Form 8-K - Current report |
| 07/27/2010 |
8-K
| Form 8-K - Current report |
| 05/06/2010 |
8-K
| Form 8-K - Current report |
| 03/10/2010 |
8-K
| Form 8-K - Current report |
| 10/27/2009 |
8-K
| Form 8-K - Current report |
| 07/28/2009 |
8-K
| Form 8-K - Current report |
| 04/28/2009 |
8-K
| Form 8-K - Current report |
| 02/19/2009 |
8-K
| Form 8-K - Current report |
| 10/28/2008 |
8-K
| Form 8-K - Current report |
| 07/29/2008 |
8-K
| Form 8-K - Current report |
| 04/25/2008 |
8-K
| Form 8-K - Current report |
| 02/21/2008 |
8-K
| Form 8-K - Current report |
| 10/25/2007 |
8-K
| Form 8-K - Current report |
| 07/26/2007 |
8-K
| Form 8-K - Current report |
| 04/25/2007 |
8-K
| Form 8-K - Current report |
| 02/22/2007 |
8-K
| Form 8-K - Current report |
|
|
|